1. Search Result
Search Result
Results for "

prostate

" in MedChemExpress (MCE) Product Catalog:

664

Inhibitors & Agonists

2

Screening Libraries

2

Fluorescent Dye

4

Biochemical Assay Reagents

52

Peptides

10

Inhibitory Antibodies

96

Natural
Products

16

Recombinant Proteins

22

Isotope-Labeled Compounds

5

Antibodies

4

Click Chemistry

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-NP017

    PSA; Native human prostate specific antigen protein

    Prostaglandin Receptor Endocrinology
    Prostate specific antigen protein (human) is a serine protease which produced by prostatic epithelium. Prostate specific antigen protein (human) can be used to study prostatic cancer .
    Prostate specific antigen protein (human)
  • HY-P5990

    PSMA Cancer
    Prostate Specific Antigen Substrate is a prostate specific antigen (PSA) fluorescent substrate. Prostate Specific Antigen Substrate can be used for detect enzymatic activity of PSA .
    Prostate Specific Antigen Substrate
  • HY-N8856

    Others Others
    Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .
    Angelol M
  • HY-164395

    Phosphatase Inflammation/Immunology Cancer
    Sipuleucel-T is a cancer vaccine. Sipuleucel-T recognizes prostatic acid phosphatase (PAP), present PAP antigens, and stimulates the immune response against prostate cancer cells .
    Sipuleucel-T
  • HY-105164

    BBR 3576

    Others Cancer
    Topixantrone (BBR 3576) is an antitumor agent, and shows antitumor activity on prostate carcinoma .
    Topixantrone
  • HY-118091A

    LY300502

    Others Cancer
    Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer .
    Bexlosteride
  • HY-105217

    FCE 26073

    5 alpha Reductase Metabolic Disease
    Turosteride is a selective 5 alpha-reductase inhibitor, with IC50 values of 55 and 53 nM for human and rat prostatic 5 alpha-reductases, respectively. Turosteride can reduce the prostate and seminal vesicle weights .
    Turosteride
  • HY-P2450

    Antibiotic P168

    Fungal Antibiotic Infection Cancer
    Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies .
    Leucinostatin A
  • HY-129615

    PSMA Cancer
    MIP-1072 is a small molecule specific prostate-specific membrane antigen (PSMA) inhibitor. MIP-1072 inhibits the glutamate carboxypeptidase activity of PSMA with an Ki value of 4.6 nM. MIP-1072 is promising for research of prostate cancer .
    MIP-1072
  • HY-N8850

    Others Cancer
    Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC50 value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .
    Angelol G
  • HY-130574

    BMX-010 chloride

    Reactive Oxygen Species Cancer
    MnTE-2-PyP (BMX-010) chloride is a ROS scavenger and potent radioprotector. MnTE-2-PyP also is a manganese porphyrin, protects normal prostate tissue from radiation damage. MnTE-2-PyP can be used for the research of diabetic prostate cancer .
    MnTE-2-PyP chloride
  • HY-N10491

    P-glycoprotein Cancer
    Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer .
    Spongionellol A
  • HY-14249
    Bicalutamide
    10+ Cited Publications

    Androgen Receptor Autophagy Cancer
    Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .
    Bicalutamide
  • HY-B0192A
    Alfuzosin hydrochloride
    1 Publications Verification

    SL 77499-10

    Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride
  • HY-B0192
    Alfuzosin
    1 Publications Verification

    SL 77499

    Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin
  • HY-P5290

    PSMA Cancer
    HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research .
    HYNIC-PSMA
  • HY-136383
    AZA1
    1 Publications Verification

    Rac1/Cdc42-IN-1

    Ras Apoptosis Cancer
    AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion .
    AZA1
  • HY-P99239

    HUJ-591

    PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
    Rosopatamab
  • HY-W013272

    HFT

    Androgen Receptor Cancer
    Hydroxyflutamide (HF), an active metabolite of Flutamide, is a potent androgen receptor antagonist (IC50=700 nM). Hydroxyflutamide can be used for the research of prostate cancer .
    Hydroxyflutamide
  • HY-N7924

    Others Inflammation/Immunology Cancer
    Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research .
    Astragenol
  • HY-110154

    Histone Demethylase Cancer
    NSC636819 is a competitive and selective inhibitor of KDM4A/KDM4B. KDM4A/KDM4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer .
    NSC636819
  • HY-P1442

    Adrenergic Receptor Cancer
    AdTx1 is a selective α1A-adrenoceptor antagonist (Ki: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .
    AdTx1
  • HY-70002
    Enzalutamide
    145+ Cited Publications

    MDV3100

    Androgen Receptor Autophagy Cancer
    Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator .
    Enzalutamide
  • HY-P99188

    CNTO 888

    CCR Cancer
    Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .
    Carlumab
  • HY-163641

    Androgen Receptor Cancer
    AR Degrader-1 is an androgen receptor (AR) monovalent degrader. AR Degrader-1 degrades AR without obvious cytotoxicity in LNCaP prostate cancer cells .
    AR Degrader-1
  • HY-138641
    Bavdegalutamide
    3 Publications Verification

    ARV-110

    Androgen Receptor Cancer
    Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer .
    Bavdegalutamide
  • HY-153772

    Androgen Receptor Cancer
    Androgen receptor antagonist 8 (Example 13) is an androgen receptor antagonist. Androgen receptor antagonist 8 inhibits prostate specific antigen secretion in LNcap cell (IC50: 88 nM). Androgen receptor antagonist 8 can be used for prostate cancer research .
    Androgen receptor antagonist 8
  • HY-B0192AR

    Adrenergic Receptor Endocrinology
    Alfuzosin (hydrochloride) (Standard) is the analytical standard of Alfuzosin (hydrochloride). This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride (Standard)
  • HY-N10492

    P-glycoprotein Cancer
    Spongionellol A analog 1, an analog of Spongionellol A (HY-10491), is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A analog 1 has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A analog 1 can be used in the research of cancers, such as prostate cancer .
    Spongionellol A analog 1
  • HY-163610

    Ligands for Target Protein for PROTAC Aldose Reductase Cancer
    AKR1C3-IN-13 (Compound 4) is an AKR1C3 inhibitor. AKR1C3-IN-13 degrades AKR1C3 in prostate cancer cells .
    AKR1C3-IN-13
  • HY-119001

    Others Cancer
    BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance .
    BKM1644
  • HY-105173

    EP 24332

    GnRH Receptor Histamine Receptor Endocrinology Cancer
    Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .
    Teverelix
  • HY-P0013

    D-21074; ORF 23541

    GnRH Receptor Cancer
    Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer.
    Antide
  • HY-101826A

    Phosphodiesterase (PDE) Cancer
    ER21355 hydrochloride is the hydrochloride form of ER21355 (HY-101826). ER21355 hydrochloride is an inhibitor for phosphodiesterase (PDE), which is potent for ameliorating benign prostatic hyperplasia (BPH) and prostatism through increasing levels of cAMP and cGMP, and resulting a relaxation of the smooth muscle cell .
    ER21355 hydrochloride
  • HY-162686

    c-Myc Cancer
    MYC-IN-3 (compound 37) is a potent MYC inhibitor. MYC-IN-3 shows antiproliferative activity. MYC-IN-3 shows anticancer activity. MYC-IN-3 has the potential for the research of prostate cancer .
    MYC-IN-3
  • HY-14249S1

    Androgen Receptor Autophagy Isotope-Labeled Compounds Cancer
    Bicalutamide-d5 is deuterated labeled Bicalutamide (HY-14249). Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .
    Bicalutamide-d5
  • HY-14249R

    Androgen Receptor Autophagy Cancer
    Bicalutamide (Standard) is the analytical standard of Bicalutamide. This product is intended for research and analytical applications. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .
    Bicalutamide (Standard)
  • HY-P3501

    NX-1207 free acid

    Apoptosis Cancer
    Fexapotide (NX-1207 free acid) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
    Fexapotide
  • HY-P3501A

    NX-1207 TFA

    Apoptosis Cancer
    Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
    Fexapotide TFA
  • HY-164477

    Androgen Receptor Cancer
    FL442 is an Androgen Receptor (AR) modulator. FL442 exhibits strong inhibitory effects in AR-dependent prostate cancer cells, showing similar inhibitory efficiency to traditional antiandrogen drugs Bicalutamide (HY-14249) and Enzalutamide (HY-70002), while maintaining antiandrogenic activity against the AR mutant F876L, which is highly resistant to Enzalutamide. Pharmacokinetic studies of FL442 in mice reveal a long half-life (8 hours), good targeting (prostate tissue), and metabolic stability, and it effectively inhibits LNCaP tumor growth at low plasma concentrations (30 ng/mL) .
    FL442
  • HY-124292
    Honokiol DCA
    1 Publications Verification

    Honokiol dichloroacetate

    Androgen Receptor Cancer
    Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level .
    Honokiol DCA
  • HY-W013272R

    Androgen Receptor Cancer
    Hydroxyflutamide (Standard) is the analytical standard of Hydroxyflutamide. This product is intended for research and analytical applications. Hydroxyflutamide (HF), an active metabolite of Flutamide, is a potent androgen receptor antagonist (IC50=700 nM). Hydroxyflutamide can be used for the research of prostate cancer .
    Hydroxyflutamide (Standard)
  • HY-B0391B

    KT-611 hydrochloride; BM-15275 hydrochloride

    Adrenergic Receptor Cancer
    Naftopidil hydrochloride (KT-611 hydrochloride) is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil hydrochloride has antiproliferative effects. Naftopidil hydrochloride can be used for the research of prostate hyperplasia .
    Naftopidil hydrochloride
  • HY-78884

    Amino Acid Derivatives Cancer
    Anticancer agent 9, a glycine derivative, is an anticancer agent. Anticancer agent 9 can inhibit tumor cells viability of myelogenous leukemia and human prostate cancer .
    Anticancer agent 9
  • HY-70002S1

    MDV3100-d6

    Androgen Receptor Cancer
    Enzalutamide-d6 is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1].
    Enzalutamide-d6
  • HY-16498

    PCK-3145

    Apoptosis Cancer
    Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels .
    Tigapotide
  • HY-125399

    HBED-CC-PSMA

    PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
    PSMA-11
  • HY-N3999

    ESK246

    Others Cancer
    Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC50 of 8.12 μM .
    Venuloside A
  • HY-120736

    Others Cancer
    MEB55 is an antitumor agent. MEB55 shows anti-proliferative activity. MEB55 has the potential for the research of prostate cancer .
    MEB55
  • HY-70002R

    Androgen Receptor Autophagy Cancer
    Enzalutamide (Standard) is the analytical standard of Enzalutamide. This product is intended for research and analytical applications. Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator .
    Enzalutamide (Standard)